Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19...(les - Biomaterials ...),Health

Net Sales - Endovascular $3.0 $1.9 56%

Total Net Sales $24.7 $21.8 13%

Royalty Income $12.6 $11.8 6%

Total Revenues $37.2 $33.6 11%

Income from Operations, As Reported $3.0 $3.7 (19%)

Earnings Per Share, As Reported $0.19 $0.24 (21%)

Adjustments to Income from Operations:

Discontinuation of Embolic Protection $0.3 - n/m

Acceleration of Stock Awards $3.0 - n/m

Income from Operations, As Adjusted $6.3 $3.7 69%

Earnings Per Share, As Adjusted $0.36 $0.24 50%

Supplemental Information Related to Equity

Compensation Expense:

1st Quarter Equity Compensation

Expense Prior to Acceleration

(includes mark-to-market adjustment

for stock appreciation rights before

and after acceleration) $0.7 $0.7

2nd Quarter Equity Compensation

Expense $0.7 $0.9

Equity Compensation Related to

Acceleration of Stock Awards $3.0 -

Total Equity Compensation Expense $4.4 $1.6

Equity Compensation Expense Per

Share (net of tax) $0.23 $0.09

Biomaterials Update. Biomaterials sales for the second quarter and six months of fiscal 2008 increased to $11.5 and $21.7 million, respectively, from $10.0 and $19.8 million, respectively, in the prior fiscal year periods. Additional details are summarized below:

Three Months Year over Six Months Year over

Ended December 31, Year %
'/>"/>